SCLX (Scilex Holding Co) PEG Ratio: N/A (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SCLX Scilex Holding Co SCLX
55 GF Score
Price $7.95
GF Value $5.90
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Scilex Holding Co PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Scilex Holding Co's PE Ratio without NRI is 0.00. Scilex Holding Co's 5-Year EBITDA growth rate is -24.40%. Therefore, Scilex Holding Co's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Scilex Holding Co's PEG Ratio or its related term are showing as below:



SCLX's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.77
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Scilex Holding Co  (NAS:SCLX) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Scilex Holding Co PEG Ratio Related Terms


Scilex Holding Co PEG Ratio Historical Data

* Premium members only.

The historical data trend for Scilex Holding Co's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scilex Holding Co PEG Ratio Chart

Scilex Holding Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PEG Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Scilex Holding Co Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

SCLX vs MIRA, NSRX, MDCX: PEG Ratio Comparison

For the Drug Manufacturers - General subindustry, Scilex Holding Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Scilex Holding Co PEG Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Scilex Holding Co's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Scilex Holding Co's PEG Ratio falls into.


SCLX
55GF Score
Scilex Holding Co SCLX
PEG Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scilex Holding Co PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Scilex Holding Co's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=/-24.40
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.

Is Scilex Holding Co (SCLX) Overvalued in 2026?

Based on GuruFocus' analysis, Scilex Holding Co stock appears to be overvalued. The current stock price of $7.95 is trading 34.7% above its estimated GF Value™ of $5.90. GuruFocus considers Scilex Holding Co to be Significantly Overvalued.

Key valuation signals for SCLX:

  • PEG Ratio: N/A
  • GF Value™: $5.90 vs. price of $7.95 (34.7% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the SCLX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Scilex Holding Co Business Description

Other Exchanges D8B0:Germany
Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
55GF Score

Get the complete analysis for SCLX

PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.95
Price
$5.90
GF Value